Summary

The global Viral Vector-Based Gene Therapy Drugs market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Viral vector-based gene therapy drugs are pharmaceutical products that use viral vectors to deliver therapeutic genes into target cells for the treatment of genetic disorders or diseases. These drugs typically contain modified viruses as vectors to efficiently and safely transfer genetic material into the cells of patients, aiming to correct genetic mutations or induce specific therapeutic effects.
In 2025, the North America Viral Vector-Based Gene Therapy Drugs market was US$ million, while the Europe market stood at US$ million. North America accounted for % of the global market in 2025 and Europe for %. Europe’s share is expected to reach % by 2032, corresponding to a CAGR of % over the analysis period.
The global key players of Viral Vector-Based Gene Therapy Drugs include GSK, MolMed, GILD, JW Therapeutics, Sibiono, Latima, Novartis, Bluebird Bio, Thermo Fisher Scientific, Intas, among others. In 2025, the top five players accounted for approximately % of global market revenue.
In terms of revenue, the top three players in North America accounted for about % of the market in 2025, while the top three in Europe held nearly %.
The global Viral Vector-Based Gene Therapy Drugs market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.
Market Segmentation
By Company:
GSK
MolMed
GILD
JW Therapeutics
Sibiono
Latima
Novartis
Bluebird Bio
Thermo Fisher Scientific
Intas
BMS
Orchard Therapeutics
Shanghai Sunway Biotech
uniQure
Spark Therapeutics
Segment by Type
Retroviral Vector
Adenovirus Vector
Lentiviral Vector
Others
Segment by Application
Hospital
Diagnostic and Testing Laboratories
Academic and Research Organizations
Others
By Region
Macro-Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Markets
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
(Additional regions can be customized based on client needs.)
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term)
Chapter 2: Quantitative analysis of Viral Vector-Based Gene Therapy Drugs market size and growth potential at global, regional, and country levels
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus)
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities
Chapter 6: Regional revenue breakdown by company, type, application and customer
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Viral Vector-Based Gene Therapy Drugs value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032
1.2.2 Retroviral Vector
1.2.3 Adenovirus Vector
1.2.4 Lentiviral Vector
1.2.5 Others
1.3 Market by Application
1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032
1.3.2 Hospital
1.3.3 Diagnostic and Testing Laboratories
1.3.4 Academic and Research Organizations
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered

2 Global Growth Trends
2.1 Global Viral Vector-Based Gene Therapy Drugs Market Perspective (2021-2032)
2.2 Global Market Size by Region: 2021 vs 2025 vs 2032
2.3 Global Viral Vector-Based Gene Therapy Drugs Market Share by Revenue, by Region (2021-2026)
2.4 Global Viral Vector-Based Gene Therapy Drugs Revenue Forecast by Region (2027-2032)
2.5 Major Regions and Emerging Markets Analysis
2.5.1 North America Viral Vector-Based Gene Therapy Drugs Market Size and Prospective (2021-2032)
2.5.2 Europe Viral Vector-Based Gene Therapy Drugs Market Size and Prospective (2021-2032)
2.5.3 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size and Prospective (2021-2032)
2.5.4 Latin America Viral Vector-Based Gene Therapy Drugs Market Size and Prospective (2021-2032)
2.5.5 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size and Prospective (2021-2032)

3 Breakdown Data by Type
3.1 Global Viral Vector-Based Gene Therapy Drugs Historical Market Size by Type (2021-2026)
3.2 Global Viral Vector-Based Gene Therapy Drugs Forecasted Market Size by Type (2027-2032)
3.3 Representative Players for Different Types of Viral Vector-Based Gene Therapy Drugs

4 Breakdown Data by Application
4.1 Global Viral Vector-Based Gene Therapy Drugs Historical Market Size by Application (2021-2026)
4.2 Global Viral Vector-Based Gene Therapy Drugs Forecasted Market Size by Application (2027-2032)
4.3 New Sources of Growth in Viral Vector-Based Gene Therapy Drugs Applications

5 Competitive Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Viral Vector-Based Gene Therapy Drugs Players by Revenue (2021-2026)
5.1.2 Global Viral Vector-Based Gene Therapy Drugs Market Share by Revenue, by Players (2021-2026)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Viral Vector-Based Gene Therapy Drugs Revenue
5.4 Global Viral Vector-Based Gene Therapy Drugs Market Concentration Analysis
5.4.1 Global Viral Vector-Based Gene Therapy Drugs Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Viral Vector-Based Gene Therapy Drugs Revenue in 2025
5.5 Global Key Players of Viral Vector-Based Gene Therapy Drugs Head Offices and Areas Served
5.6 Global Key Players of Viral Vector-Based Gene Therapy Drugs, Product and Application
5.7 Global Key Players of Viral Vector-Based Gene Therapy Drugs, Date of Entry into This Industry
5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Viral Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026)
6.1.2 North America Market Size by Type
6.1.2.1 North America Viral Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026)
6.1.2.2 North America Viral Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
6.1.3 North America Market Size by Application
6.1.3.1 North America Viral Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026)
6.1.3.2 North America Viral Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
6.1.4 North America Viral Vector-Based Gene Therapy Drugs Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Viral Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Viral Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026)
6.2.2.2 Europe Viral Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Viral Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026)
6.2.3.2 Europe Viral Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
6.2.4 Europe Viral Vector-Based Gene Therapy Drugs Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 Asia-Pacific Market: Players, Segments, Downstream and Major Customers
6.3.1 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026)
6.3.2.2 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026)
6.3.3.2 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
6.3.4 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Major Customers
6.3.5 Asia-Pacific Market Trends and Opportunities
6.4 Latin America Market: Players, Segments, Downstream and Major Customers
6.4.1 Latin America Viral Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America Viral Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026)
6.4.2.2 Latin America Viral Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America Viral Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026)
6.4.3.2 Latin America Viral Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
6.4.4 Latin America Viral Vector-Based Gene Therapy Drugs Major Customers
6.4.5 Latin America Market Trends and Opportunities
6.5 Middle East & Africa Market: Players, Segments, Downstream and Major Customers
6.5.1 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026)
6.5.2.2 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026)
6.5.3.2 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
6.5.4 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Major Customers
6.5.5 Middle East & Africa Market Trends and Opportunities

7 Key Player Profiles
7.1 GSK
7.1.1 GSK Company Details
7.1.2 GSK Business Overview
7.1.3 GSK Viral Vector-Based Gene Therapy Drugs Introduction
7.1.4 GSK Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
7.1.5 GSK Recent Development
7.2 MolMed
7.2.1 MolMed Company Details
7.2.2 MolMed Business Overview
7.2.3 MolMed Viral Vector-Based Gene Therapy Drugs Introduction
7.2.4 MolMed Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
7.2.5 MolMed Recent Development
7.3 GILD
7.3.1 GILD Company Details
7.3.2 GILD Business Overview
7.3.3 GILD Viral Vector-Based Gene Therapy Drugs Introduction
7.3.4 GILD Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
7.3.5 GILD Recent Development
7.4 JW Therapeutics
7.4.1 JW Therapeutics Company Details
7.4.2 JW Therapeutics Business Overview
7.4.3 JW Therapeutics Viral Vector-Based Gene Therapy Drugs Introduction
7.4.4 JW Therapeutics Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
7.4.5 JW Therapeutics Recent Development
7.5 Sibiono
7.5.1 Sibiono Company Details
7.5.2 Sibiono Business Overview
7.5.3 Sibiono Viral Vector-Based Gene Therapy Drugs Introduction
7.5.4 Sibiono Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
7.5.5 Sibiono Recent Development
7.6 Latima
7.6.1 Latima Company Details
7.6.2 Latima Business Overview
7.6.3 Latima Viral Vector-Based Gene Therapy Drugs Introduction
7.6.4 Latima Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
7.6.5 Latima Recent Development
7.7 Novartis
7.7.1 Novartis Company Details
7.7.2 Novartis Business Overview
7.7.3 Novartis Viral Vector-Based Gene Therapy Drugs Introduction
7.7.4 Novartis Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
7.7.5 Novartis Recent Development
7.8 Bluebird Bio
7.8.1 Bluebird Bio Company Details
7.8.2 Bluebird Bio Business Overview
7.8.3 Bluebird Bio Viral Vector-Based Gene Therapy Drugs Introduction
7.8.4 Bluebird Bio Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
7.8.5 Bluebird Bio Recent Development
7.9 Thermo Fisher Scientific
7.9.1 Thermo Fisher Scientific Company Details
7.9.2 Thermo Fisher Scientific Business Overview
7.9.3 Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Introduction
7.9.4 Thermo Fisher Scientific Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
7.9.5 Thermo Fisher Scientific Recent Development
7.10 Intas
7.10.1 Intas Company Details
7.10.2 Intas Business Overview
7.10.3 Intas Viral Vector-Based Gene Therapy Drugs Introduction
7.10.4 Intas Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
7.10.5 Intas Recent Development
7.11 BMS
7.11.1 BMS Company Details
7.11.2 BMS Business Overview
7.11.3 BMS Viral Vector-Based Gene Therapy Drugs Introduction
7.11.4 BMS Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
7.11.5 BMS Recent Development
7.12 Orchard Therapeutics
7.12.1 Orchard Therapeutics Company Details
7.12.2 Orchard Therapeutics Business Overview
7.12.3 Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Introduction
7.12.4 Orchard Therapeutics Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
7.12.5 Orchard Therapeutics Recent Development
7.13 Shanghai Sunway Biotech
7.13.1 Shanghai Sunway Biotech Company Details
7.13.2 Shanghai Sunway Biotech Business Overview
7.13.3 Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Introduction
7.13.4 Shanghai Sunway Biotech Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
7.13.5 Shanghai Sunway Biotech Recent Development
7.14 uniQure
7.14.1 uniQure Company Details
7.14.2 uniQure Business Overview
7.14.3 uniQure Viral Vector-Based Gene Therapy Drugs Introduction
7.14.4 uniQure Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
7.14.5 uniQure Recent Development
7.15 Spark Therapeutics
7.15.1 Spark Therapeutics Company Details
7.15.2 Spark Therapeutics Business Overview
7.15.3 Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Introduction
7.15.4 Spark Therapeutics Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
7.15.5 Spark Therapeutics Recent Development

8 Viral Vector-Based Gene Therapy Drugs Market Dynamics
8.1 Viral Vector-Based Gene Therapy Drugs Industry Trends
8.2 Viral Vector-Based Gene Therapy Drugs Market Drivers
8.3 Viral Vector-Based Gene Therapy Drugs Market Challenges
8.4 Viral Vector-Based Gene Therapy Drugs Market Restraints

9 Research Findings and Conclusion

10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Viral Vector-Based Gene Therapy Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Global Viral Vector-Based Gene Therapy Drugs Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 3. Global Market Viral Vector-Based Gene Therapy Drugs Market Size (US$ Million) by Region:2021 vs 2025 vs 2032
Table 4. Global Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) Market Share by Region (2021-2026)
Table 5. Global Viral Vector-Based Gene Therapy Drugs Revenue Share by Region (2021-2026)
Table 6. Global Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) Forecast by Region (2027-2032)
Table 7. Global Viral Vector-Based Gene Therapy Drugs Revenue Share Forecast by Region (2027-2032)
Table 8. Global Viral Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 9. Global Viral Vector-Based Gene Therapy Drugs Market Share by Revenue, by Type (2021-2026)
Table 10. Global Viral Vector-Based Gene Therapy Drugs Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 11. Global Viral Vector-Based Gene Therapy Drugs Market Share by Revenue, by Type (2027-2032)
Table 12. Representative Players of Each Type
Table 13. Global Viral Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 14. Global Viral Vector-Based Gene Therapy Drugs Market Share by Revenue, by Application (2021-2026)
Table 15. Global Viral Vector-Based Gene Therapy Drugs Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 16. Global Viral Vector-Based Gene Therapy Drugs Market Share by Revenue, by Application (2027-2032)
Table 17. New Sources of Growth in Viral Vector-Based Gene Therapy Drugs Applications
Table 18. Global Viral Vector-Based Gene Therapy Drugs Revenue by Players (2021-2026) & (US$ Million)
Table 19. Global Viral Vector-Based Gene Therapy Drugs Market Share by Players (2021-2026)
Table 20. Global Top Viral Vector-Based Gene Therapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector-Based Gene Therapy Drugs as of 2025)
Table 21. Ranking of Global Top Viral Vector-Based Gene Therapy Drugs Companies by Revenue (US$ Million) in 2025
Table 22. Global 5 Largest Players Market Share by Viral Vector-Based Gene Therapy Drugs Revenue (CR5 and HHI) & (2021-2026)
Table 23. Global Key Players of Viral Vector-Based Gene Therapy Drugs, Headquarters and Area Served
Table 24. Global Key Players of Viral Vector-Based Gene Therapy Drugs, Product and Application
Table 25. Global Key Players of Viral Vector-Based Gene Therapy Drugs, Date of Entry into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Viral Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026) & (US$ Million)
Table 28. North America Viral Vector-Based Gene Therapy Drugs Market Share by Revenue, by Company (2021-2026)
Table 29. North America Viral Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 30. North America Viral Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 31. Europe Viral Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026) & (US$ Million)
Table 32. Europe Viral Vector-Based Gene Therapy Drugs Market Share by Revenue, by Company (2021-2026)
Table 33. Europe Viral Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 34. Europe Viral Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 35. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026) & (US$ Million)
Table 36. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Share by Revenue, by Company (2021-2026)
Table 37. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 38. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 39. Latin America Viral Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026) & (US$ Million)
Table 40. Latin America Viral Vector-Based Gene Therapy Drugs Market Share by Revenue, by Company (2021-2026)
Table 41. Latin America Viral Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 42. Latin America Viral Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 43. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Share by Revenue, by Company (2021-2026)
Table 45. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 46. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 47. GSK Company Details
Table 48. GSK Business Overview
Table 49. GSK Viral Vector-Based Gene Therapy Drugs Product
Table 50. GSK Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 51. GSK Recent Development
Table 52. MolMed Company Details
Table 53. MolMed Business Overview
Table 54. MolMed Viral Vector-Based Gene Therapy Drugs Product
Table 55. MolMed Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 56. MolMed Recent Development
Table 57. GILD Company Details
Table 58. GILD Business Overview
Table 59. GILD Viral Vector-Based Gene Therapy Drugs Product
Table 60. GILD Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 61. GILD Recent Development
Table 62. JW Therapeutics Company Details
Table 63. JW Therapeutics Business Overview
Table 64. JW Therapeutics Viral Vector-Based Gene Therapy Drugs Product
Table 65. JW Therapeutics Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 66. JW Therapeutics Recent Development
Table 67. Sibiono Company Details
Table 68. Sibiono Business Overview
Table 69. Sibiono Viral Vector-Based Gene Therapy Drugs Product
Table 70. Sibiono Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 71. Sibiono Recent Development
Table 72. Latima Company Details
Table 73. Latima Business Overview
Table 74. Latima Viral Vector-Based Gene Therapy Drugs Product
Table 75. Latima Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 76. Latima Recent Development
Table 77. Novartis Company Details
Table 78. Novartis Business Overview
Table 79. Novartis Viral Vector-Based Gene Therapy Drugs Product
Table 80. Novartis Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 81. Novartis Recent Development
Table 82. Bluebird Bio Company Details
Table 83. Bluebird Bio Business Overview
Table 84. Bluebird Bio Viral Vector-Based Gene Therapy Drugs Product
Table 85. Bluebird Bio Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 86. Bluebird Bio Recent Development
Table 87. Thermo Fisher Scientific Company Details
Table 88. Thermo Fisher Scientific Business Overview
Table 89. Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Product
Table 90. Thermo Fisher Scientific Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 91. Thermo Fisher Scientific Recent Development
Table 92. Intas Company Details
Table 93. Intas Business Overview
Table 94. Intas Viral Vector-Based Gene Therapy Drugs Product
Table 95. Intas Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 96. Intas Recent Development
Table 97. BMS Company Details
Table 98. BMS Business Overview
Table 99. BMS Viral Vector-Based Gene Therapy Drugs Product
Table 100. BMS Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 101. BMS Recent Development
Table 102. Orchard Therapeutics Company Details
Table 103. Orchard Therapeutics Business Overview
Table 104. Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Product
Table 105. Orchard Therapeutics Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 106. Orchard Therapeutics Recent Development
Table 107. Shanghai Sunway Biotech Company Details
Table 108. Shanghai Sunway Biotech Business Overview
Table 109. Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Product
Table 110. Shanghai Sunway Biotech Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 111. Shanghai Sunway Biotech Recent Development
Table 112. uniQure Company Details
Table 113. uniQure Business Overview
Table 114. uniQure Viral Vector-Based Gene Therapy Drugs Product
Table 115. uniQure Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 116. uniQure Recent Development
Table 117. Spark Therapeutics Company Details
Table 118. Spark Therapeutics Business Overview
Table 119. Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Product
Table 120. Spark Therapeutics Revenue in Viral Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 121. Spark Therapeutics Recent Development
Table 122. Viral Vector-Based Gene Therapy Drugs Market Trends
Table 123. Viral Vector-Based Gene Therapy Drugs Market Drivers
Table 124. Viral Vector-Based Gene Therapy Drugs Market Challenges
Table 125. Viral Vector-Based Gene Therapy Drugs Market Restraints
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources

List of Figures
Figure 1. Viral Vector-Based Gene Therapy Drugs Product Picture
Figure 2. Global Viral Vector-Based Gene Therapy Drugs Market Share by Type: 2025 vs 2032
Figure 3. Retroviral Vector Features
Figure 4. Adenovirus Vector Features
Figure 5. Lentiviral Vector Features
Figure 6. Others Features
Figure 7. Global Viral Vector-Based Gene Therapy Drugs Market Share by Application: 2025 vs 2032
Figure 8. Hospital
Figure 9. Diagnostic and Testing Laboratories
Figure 10. Academic and Research Organizations
Figure 11. Others
Figure 12. Viral Vector-Based Gene Therapy Drugs Report Years Considered
Figure 13. Global Viral Vector-Based Gene Therapy Drugs Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 14. Global Viral Vector-Based Gene Therapy Drugs Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Viral Vector-Based Gene Therapy Drugs Market Share by Revenue, by Region: 2021 vs 2025
Figure 16. North America Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) Growth Rate (2021-2032)
Figure 17. Europe Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) Growth Rate (2021-2032)
Figure 18. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) Growth Rate (2021-2032)
Figure 19. Latin America Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) Growth Rate (2021-2032)
Figure 20. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) Growth Rate (2021-2032)
Figure 21. Global Viral Vector-Based Gene Therapy Drugs Market Share by Players in 2025
Figure 22. Global Top Viral Vector-Based Gene Therapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector-Based Gene Therapy Drugs as of 2025)
Figure 23. The Top 10 and 5 Players Market Share by Viral Vector-Based Gene Therapy Drugs Revenue in 2025
Figure 24. North America Viral Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
Figure 25. North America Viral Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
Figure 26. Europe Viral Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
Figure 27. Europe Viral Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
Figure 28. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
Figure 29. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
Figure 30. Latin America Viral Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
Figure 31. Latin America Viral Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
Figure 32. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
Figure 33. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
Figure 34. GSK Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 35. MolMed Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 36. GILD Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 37. JW Therapeutics Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 38. Sibiono Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 39. Latima Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 40. Novartis Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 41. Bluebird Bio Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 42. Thermo Fisher Scientific Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 43. Intas Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 44. BMS Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 45. Orchard Therapeutics Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 46. Shanghai Sunway Biotech Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 47. uniQure Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 48. Spark Therapeutics Revenue Growth Rate in Viral Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed